Therapeutic potential of intravenous 67‐gallium in non‐Hodgkin's lymphoma

P. C. Huijgens*, A. R. Jonkhoff, O. S. Hoekstra, G. J. Ossenkoppele, G. J.J. Teule

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Abstract: 67‐gallium accumulates rather selectively in malignant lymphoid tissue. The isotope has a substantial cytotoxic effect in human‐derived cell‐lines. 67‐gallium was given intravenously to 3 patients with end‐stage, resistant large‐cell lymphoma. Evaluation of tumour response was done by physical measurements, and CT‐scanning together with gallium scintigraphy. Three weekly doses of 20, 40 and 60 mCi respectively caused persistent pancytopenia in 1 patient. Panycytopenia was not observed in 2 other patients given two 40 mCi doses 4 weeks apart. In all 3 patients, some response was noted, be it shortlived and different from site to site. 67‐gallium has some cytostatic effect in large cell lymphoma. It seems feasible to start a phase I study to find a tolerable dose to be given every 4 weeks.

Original languageEnglish
Pages (from-to)206-208
Number of pages3
JournalEuropean Journal of Haematology
Volume51
Issue number4
DOIs
Publication statusPublished - Oct 1993

Cite this